News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Celgene (CELG) Release: Oral OTEZLA® (Apremilast) Showed Long-Term Clinical Benefits In Patients With Active Psoriatic Arthritis



6/11/2014 8:06:37 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG), today announced results of additional analyses from the phase III clinical trials of OTEZLA, the Company’s oral, selective inhibitor of phosphodiesterase 4 (PDE4). These included long-term (52-week) analyses from the PALACE 1, 2 and 3 trials of the impact of OTEZLA on psoriatic arthritis disease activity, safety and tolerability, in addition to a separate 16-week work productivity analysis from PALACE 1. The findings were presented at the European League Against Rheumatism Annual Congress (EULAR 2014) in Paris, France.

Help employers find you! Check out all the jobs and post your resume.



comments powered by Disqus
Celgene
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES